Evidence map›Paper›PMID 28352363›Full record

ArticleExperimental and therapeutic medicine2017

Role of microRNA-130a in myocardial hypoxia/reoxygenation injury.

Hongyan Liu, Lei Huan, Jie Yin, Meiling Qin, Zengtang Zhang, Zhiqiang Zhang, Junye Zhang, Shu Wang

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.Current treatment options in oncology · 2021
    Review
  11. Article
  12. Article
  13. Review
  14. Hypoxia drives cardiac miRNAs and inflammation in the right and left ventricle.Journal of molecular medicine (Berlin, Germany) · 2019
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hongyan LiuDepartment of Cardiology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China.
Lei HuanDepartment of Cardiology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China.
Jie YinDepartment of Cardiology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China.
Meiling QinDepartment of Endocrinology, Traditional Chinese Medical Hospital of Laiwu, Laiwu, Shandong 271100, P.R. China.
Zengtang ZhangDepartment of Cardiology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China.
Zhiqiang ZhangDepartment of Cardiology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China.
Junye ZhangCardiac Function Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Shu WangSino-German Laboratory, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100037, P.R. China.
Jinan City People's Hospital · CNShandong First Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNQilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the role of microRNA (miR)-130a in the pathogenesis of myocardial hypoxia/reoxygenation (H/R) injury. Primary rat cardiomyocytes were cultured and subjected to H/R treatment. Reverse transcription-quantitative polymerase chain reaction was performed to detect the levels of miR-130a, western blot analysis was used to determine the expression of various proteins, and CCK-8 assay was performed to determine cell viability. In addition, flow cytometry was used to assess apoptosis. The cell viability was significantly decreased and the apoptosis rate was significantly increased in H/R-treated primary cardiomyocytes, and the expression level of miR-130a was also elevated in these model cells. Transfection with miR-130a inhibitor significantly elevated the cell viability and reduced the apoptosis rate in H/R-treated cardiomyocytes. Bioinformatics analysis indicated that autophagy-related gene 14 (ATG14) is the target for miR-130a, which was confirmed by dual-luciferase reporter assay and western blot analysis. When the H/R model cells were co-transfected with miR-130a inhibitor and small interfering RNA against ATG14, the cell viability was significantly reduced and the apoptosis rate was significantly elevated, compared with that of cells transfected with miR-130a inhibitor alone. miR-130a inhibitor transfection significantly elevated the levels of ATG14 and phosphorylated (p-)Beclin 1, increased the LC3II/LC3I ratio, and decreased the expression levels of P62 and cleaved caspase-3, while the co-transfection of miR-130a inhibitor and siR-ATG14 attenuated these effects in H/R-induced primary cardiomyocytes. These results indicate that miR-130a is involved in H/R-induced injuries in primary cardiomyocytes, and that the inhibition of miR-130a increases the levels of ATG14 and p-Beclin 1, thereby increasing autophagy and inhibiting apoptosis in these cells.

Indexed as

apoptosisautophagyautophagy-related gene 14hypoxia/reoxygenationmicroRNAmiR–130a

Identifiers

PMID28352363
PMCPMC5348690
OpenAlexW2566032400

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.